Market Run Down; Johnson & Johnson (NYSE: JNJ) new drug and more stock news

Johnson & Johnson’s (NYSE: JNJ) submission of a supplemental New Drug

Johnson & Johnson’s submission of a supplemental New Drug Application to the FDA for Caplyta, supported by Phase 3 trial data, aims to significantly reduce schizophrenia relapse risk, highlighting its potential impact on patient adherence.

Johnson & Johnson submitted a supplemental New Drug Application to the FDA for Caplyta, aiming to expand its use for preventing schizophrenia relapse.

Horace Mann Educators Corporation (NYSE: HMH)

Innovate Springfield is relocating to the Horace Mann building in downtown Springfield, providing a larger space for the organization and its entrepreneurial endeavors.

The Fargo School Board approved a $45 million project to replace Horace Mann Elementary with a new school, combining the Roosevelt and Madison attendance areas, with temporary relocation of students during the 2026-27 and 2027-28 school years, and the new school opening in 2028.

Diversified Healthcare Trust (NASDAQ: DHC)

DHC has closed a new $150 million secured revolving credit facility, secured by 14 senior housing communities, to enhance liquidity for general business needs.

DHC has scheduled its second quarter 2025 conference call for August 5, 2025, where key executives will discuss the financial results.